Drug Pipeline and Trend Report 1H 2026

IPD Analytics has released its “Drug Pipeline and Trend Impact Report: 1H 2026,” highlighting 41 high-impact drugs across various therapeutic areas that are nearing potential approval by the FDA over the next 12 months. For each of the drugs analyzed, IPD has provided an assessment of the clinical efficacy, expected place in therapy, approval outlook, estimated cost, and anticipated reimbursement and distribution channel.

IPD Analytics releases a drug pipeline report and its biosimilar counterpart twice yearly to its network of subscribers, which includes payers, providers, brand and generic drug manufacturers, Wall Street investors, and other industry stakeholders involved in the pharmaceutical value chain.